Modalis Therapeutics Announces Promising Results for MDL-101, a Novel Epigenome Editing Treatment for LAMA2 Congenital Muscular Dystrophy (LAMA2-CMD).

Semaglutide, a cutting-edge medication, has been making significant strides in the treatment of type 2 diabetes, weight loss, and reducing cardiovascular risk.

May 9th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Inmagene Announces Encouraging Early Outcomes of Phase 2a Study on IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody, Prolonged Duration, Aimed at Treating Atopic Dermatitis.

Lepu Biopharma is an innovative biopharmaceutical company focused on the field of oncology treatment, particularly in targeted therapy and immunotherapy.

Boehringer Ingelheim has revealed encouraging results from its HORNBILL Phase I/IIa trial for BI 764524.

The U.S. FDA encompasses multiple centers including key ones like the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER).

BioAtla Receives FDA Approval to Begin Trials of BA3361, a Conditionally Active Biologic (CAB) Targeting Nectin-4 in Various Cancers.

At the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Kelun Botai Biomedicine will disclose the research progress of SKB264.

Mediar Initiates Clinical Stage for Its Unique Fibrosis Collection with Initial Group Treatment in Phase 1 Study of MTX-463, and Forms a Clinical Advisory Committee.

Special review for drugs is designed to accelerate the marketing of new drugs, especially those with significant clinical advantages or used to treat serious diseases.

GIBF commits $10 million in funding to Nectin Therapeutics for the development of innovative first-in-class immunotherapies and antibody-drug conjugates.